


## PHARMACEUTICAL 2023



## Aurinia Pharmaceuticals Inc. Rank 78 of 446





## PHARMACEUTICAL 2023



## Aurinia Pharmaceuticals Inc. Rank 78 of 446



The relative strengths and weaknesses of Aurinia Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aurinia Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Aurinia Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 220%, being 177% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	442,539
Cost of Goods Sold	5,664
Intangible Assets	6,425
Liabilities, Current	46,107
Liabilities, Non-Current	19,318
Other Assets	18,246
Other Compr. Net Income	-209
Other Expenses	305
Other Liabilities	0
Other Net Income	5,118
Other Revenues	134,030
Property and Equipment	3,650
Research and Development	44,988
Selling, General and Administrative Expense	196,371

Output Variable	Value in 1000 USD
Assets	470,860
Liabilities	65,425
Expenses	247,328
Revenues	134,030
Stockholders Equity	405,435
Net Income	-108,180
Comprehensive Net Income	-108,284
Economic Capital Ratio	220%

